Serevent salmeterol: Phase III started

Brigham and Women's Hospital began the open-label, U.S. Phase III BELT trial to compare twice-daily 50 µg Serevent salmeterol or twice-daily 12 µg Foradil formoterol plus inhaled corticosteroid controller medication (ICS) vs. 18 µg once-daily Spiriva HandiHaler tiotropium plus ICS for 1 year in 1,500 African American patients. BELT is funded by a grant from HHS's Agency for Healthcare Research and Quality (AHRQ). ...